RESUMO
The aim of the present study was to determine and characterize the activity of male Polish Premier League soccer players during elite-level matches, depending on playing position, activity intensity range, and match period. The study sample comprised 1178 players. Amisco Pro® was used to track the match activity players. Statistical analysis of the total distance covered by players revealed that the greatest distance was covered by central midfielders (11894 ± 765 m) and external midfielders (11751 ± 686 m). In terms of velocity, the greatest distance was covered by players in the V1 range (0 ≤ V1 < 11 km · h-1, standing, walking), (7028 ± 294 m). The difference between the match periods was statistically non-significant, amounting to only 0.5%. As such they could prove useful for present and future comparisons between positions and represent the scientific basis for developing position-specific conditioning/training regimes for both clubs and individuals.
Assuntos
Desempenho Atlético , Exercício Físico , Futebol , Atletas , Humanos , Masculino , PolôniaRESUMO
AIM: The aim of this study was to investigate recovery processes on pressure pain sensitivity and blood indicators in professional football players after three different post-game training modalities: standard recovery training, no physical activity, delayed onset muscle soreness reduction training. METHODS: Eleven male football field players participated in the present study. The experiment was performed in three sessions over three weeks after three football league games. The procedure was composed of the following assessments included in each session: measurement of pain pressure threshold, creatine kinase activity and myoglobin (Mb) concentration before, 24 and 48 hours after game. RESULTS: In standard recovery training there was no full recovery in deep structure sensitivity of the frontal thigh muscles at 48 hours after game (P=0.008). In the no physical activity session, sensitivity returned to its level before game. On the contrary, in the delayed onset muscle soreness reduction training sensitivity decreased 48 hours after game (P<0.001). Creatine kinase activity decreased significantly from 24 hours to 48 hours in session with no activity and delayed onset muscle soreness reduction training (P<0.05). None of the recovery methods had an influence on Mb concentration. CONCLUSION: The present study points towards a potent effect of delayed onset muscle soreness reduction training on recovery after a football game.
Assuntos
Creatina Quinase/sangue , Futebol Americano/lesões , Músculo Esquelético/lesões , Mialgia/prevenção & controle , Mialgia/fisiopatologia , Mioglobina/sangue , Educação Física e Treinamento/métodos , Adolescente , Adulto , Biomarcadores/sangue , Frequência Cardíaca/fisiologia , Humanos , Masculino , Limiar Sensorial/fisiologia , Adulto JovemRESUMO
UNLABELLED: BIBY STUDY OBJECTIVE: To obtain experience with exenatide treatment (Byetta) in patients with diabetes mellitus type 2 in a common clinical practice ofdiabetology departments. TYPE OF OBSERVATION: Observational study conducted by a randomly selected group of outpatient medical practitioners from 28 diabetology departments in the Czech Republic. OBSERVED AND ASSESSED POPULATION: 465 patients underwent at least three months of Byetta treatment; 347 persons (74.6% ofthe research population) stayed forthe extended observation of 6-12 months. Apart from the basic identification data (year of birth, sex, age when diabetes mellitus manifested, height, maximum patient weight before diabetes and when diabetes mellitus manifested), the following information was recorded in three-month intervals: weight, waistline, glycated haemoglobin (HbA(1c)), and diabetes mellitus treatment The population included 50.3% women and 49.7% men, and the average age at the time of diabetes manifestation was 48 (20-73 years). The period between the diabetes manifestation and the start of exenatide treatment was 8.3 years on average. RESULTS: The average maximum BMI value before the detection of diabetes was 39.05 (+/- 6.73); at the time of the diabetes manifestation 37.88 (+/- 6.40); and at the start of Byetta treatment 39.01 (+/- 6.22). The BMI after three, six, and 12 months of treatment was as follows: 37.86 (+/- 6.12), 37.18 (+/- 6.0), and 36.60 (+/- 6.21); it decreased by > or = 0.5 in 83.3% patients who were under observation for 12 months. HbA(1c) value decreased in the first three months from 7.39% (+/- 1.57) to 6.41% (+/- 1.34), p < 0.0001. In the period of three-six months, the value decreased to 6.22% (+/- 1.34), and after 12 months, HbA(1c) was at 6.04 (+/- 1.20). An improvement in HbA(1c) value of 0.5-2.0% occurred after the first year in 49% of our research population. The waistline was measured on a regular basis in only 267 patients (58.9%). The average initial value of 120.7 cm was reduced within three months of the treatment to 118.3 cm, and within six and 12 months to 117.3 and 112.6 cm respectively. CONCLUSION: Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 led, in 66.8% of the population, to a statistically significant reduction in HbA(1c) levels in the first three-six months of the treatment; after 12 months of treatment, 25% of the population was still showing an improvement in HbA(1c) of > 2.0%. Of observed patients, 74.4% significantly reduced their BMI (by > 0.5) during the first three months; 39.6% of patients reduced their BMI in the period of three-six months.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hemoglobinas Glicadas/análise , Hipoglicemiantes/uso terapêutico , Peptídeos/uso terapêutico , Peçonhas/uso terapêutico , Redução de Peso , Adulto , Idoso , Índice de Massa Corporal , Diabetes Mellitus Tipo 2/sangue , Exenatida , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
UNLABELLED: BIBYII STUDY OBJECTIVE: To obtain experience with longterm (24 months) exenatide treatment (Byetta) in patients with diabetes mellitus type 2 from a common clinical practice of diabetology departments in the Czech Republic. TYPE OF OBSERVATION: Observational study conducted by a randomly selected group of outpatient medical practitioners from 28 diabetology departments in the Czech Republic. OBSERVED AND ASSESSED POPULATION: From the original population of 465 patients, who underwent a minimum of three months Byetta treatment, 169 patients (36.6%) remained during the second prolonged observation after 18 months, and 76 patients completed 24 months of uninterrupted Byetta treatment. The following basic information about the patients was collected: year of birth, sex, age when diabetes mellitus (DM) manifested, height, maximum weight before diabetes and when DM manifested. The study recorded the following values in three-âmonth intervals: weight, waistline, glycated haemoglobin (HbA1c), and DM treatment. The population of the prolonged observation comprised 50.3% women and 49.7 % men, and the average age at the time of DM2 manifestation was 48.0 (20-â73 years). RESULTS: At the beginning of Byetta treatment, the average maximum BMI in the subpopulation observed for 24 months was 38.44; after 3, 6, 9, 12 and 24 months the following levels were measured, respectively: 36.79, 36.22, 35.91, 35.57 and 35.58. The original HbA1c level of 7.44% at the beginning of Byetta treatment decreased after 3, 6, 9, 12 and 24 months to 6.33, 5.98, 5.83, 5.86 and 5.93%. CONCLUSION: Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 over a period of 24 months has led to an improvement in HbA1c level by 1.51%, and BMI level was reduced by 2.37 after two years of Byetta treatment.